{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-body-groin/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field 4dcef431-ed53-4f7f-a484-a8d4013de008 --><h2>Oral itraconazole</h2><!-- end field 4dcef431-ed53-4f7f-a484-a8d4013de008 -->","summary":"","htmlStringContent":"<!-- begin item 5e047eb9-6b78-4708-a02c-a8d4013dde67 --><!-- end item 5e047eb9-6b78-4708-a02c-a8d4013dde67 -->","topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","lastRevised":"Last revised in May 2018","chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","fullItemName":"Management","slug":"management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6a4bd9d2-3c94-5e07-bf5c-f923b848ae44","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 85205ca8-1b5f-41d4-b8d3-a8d4013df5e7 --><h3>Dosing schedule</h3><!-- end field 85205ca8-1b5f-41d4-b8d3-a8d4013df5e7 -->","summary":"","htmlStringContent":"<!-- begin item ffa99087-18f9-4b7b-be95-a8d4013df482 --><!-- begin field 49d230b1-a020-44a0-a3ba-a8d4013df5e7 --><ul><li>For adults, prescribe itraconazole 100 mg once daily for 15 days, alternatively 200 mg once daily for 7 days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>] </p><!-- end field 49d230b1-a020-44a0-a3ba-a8d4013df5e7 --><!-- end item ffa99087-18f9-4b7b-be95-a8d4013df482 -->","subChapters":[]},{"id":"9636c05d-6128-58f6-b434-fbe410abaaf3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 872f4725-4467-49a4-83a2-a8d4013e139b --><h3>Contraindications and cautions</h3><!-- end field 872f4725-4467-49a4-83a2-a8d4013e139b -->","summary":"","htmlStringContent":"<!-- begin item 02cd0cef-f4a0-494a-9522-a8d4013e12b5 --><!-- begin field d6d18e5e-352d-4c50-a849-a8d4013e139b --><p><strong>Do not prescribe itraconazole to people with:</strong></p><ul><li>Acute porphyria.</li><li>Ventricular dysfunction or a history of heart failure — itraconazole has been shown to have a negative inotropic effect.</li></ul><p><strong>Prescribe itraconazole with caution in people:</strong></p><ul><li>At high risk of heart failure, including people on treatment with negative inotropic drugs (such as calcium-channel blockers).</li><li>Who are immunocompromised (for example people with AIDS, on chemotherapy, have neutropenia, or previous organ transplants).</li><li>With acute liver disease, or a history of hepatotoxicity with other drugs — consider monitoring liver function tests (LFTs). Advise immediate LFTs if symptoms of possible liver toxicity develop, such as anorexia, nausea, vomiting, fatigue, abdominal pain, or dark urine.</li><li>With renal impairment.</li><li>Taking drugs such as astemizole, pimozide, quinidine, or terfenadine that may prolong the QT interval, as there is a risk of cardiac arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>] </p><!-- end field d6d18e5e-352d-4c50-a849-a8d4013e139b --><!-- end item 02cd0cef-f4a0-494a-9522-a8d4013e12b5 -->","subChapters":[]},{"id":"50bc94b0-f26f-5d3d-996d-15dc4215672b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6c65753b-a180-476e-82ae-a8d4013e5a4b --><h3>Adverse effects</h3><!-- end field 6c65753b-a180-476e-82ae-a8d4013e5a4b -->","summary":"","htmlStringContent":"<!-- begin item c0dfc55a-1adc-4267-bc65-a8d4013e598f --><!-- begin field d3217a9e-2690-4c87-856c-a8d4013e5a4b --><p><strong>Adverse effects of itraconazole include:</strong></p><ul><li>Gastrointestinal — nausea, abdominal pain (common); vomiting, diarrhoea, constipation, dyspepsia, taste disturbance, flatulence (uncommon). Rarely pancreatitis.</li><li>Hepatobiliary — hyperbilirubinaemia (uncommon). Rarely hepatotoxicity (including acute liver failure).</li><li>Nervous system — headache, dizziness, paraesthesia (uncommon).</li><li>Skin and subcutaneous tissue — rash (common); alopecia, urticaria, pruritus (uncommon).</li><li>Other — arthralgia, myalgia, heart failure, erectile dysfunction, menstrual disorders, oedema, tinnitus, visual disturbance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>]</p><!-- end field d3217a9e-2690-4c87-856c-a8d4013e5a4b --><!-- end item c0dfc55a-1adc-4267-bc65-a8d4013e598f -->","subChapters":[]},{"id":"a1e9a632-bf00-5768-a6a2-b93bf0d92c9a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a4305e61-3c36-481c-bec7-a8d4013e9b76 --><h3>Drug interactions</h3><!-- end field a4305e61-3c36-481c-bec7-a8d4013e9b76 -->","summary":"","htmlStringContent":"<!-- begin item 72c03f2c-cccf-4d11-9efa-a8d4013e9abb --><!-- begin field c2e40277-c142-475b-923b-a8d4013e9b76 --><p><strong>Itraconazole is metabolized by the cytochrome p450 3A4 (isoenzyme CYP34A) and it interacts with a number of liver enzyme-inducing and liver enzyme-inhibiting drugs.</strong></p><ul><li>Itraconazole levels may be reduced by the following drugs:<ul><li>Carbamazepine, phenobarbital, phenytoin — monitor itraconazole efficacy and increase dose if necessary.</li><li>Rifampicin, rifabutin — monitor itraconazole efficacy and increase dose if necessary.</li><li>St John’s wort — avoid concurrent use.</li></ul></li><li>Itraconazole levels may be increased by the following drugs:<ul><li>HIV protease inhibitors (ritonavir, indinavir) — monitor for adverse effects.</li><li>Clarithromycin and erythromycin — monitor for adverse effects.</li></ul></li><li>Itraconazole may increase levels of the following drugs:<ul><li>Aliskiren — monitor for adverse effects.</li><li>Aripiprazole, quetiapine, risperidone — dose reductions may be necessary.</li><li>Quetiapine — concurrent use with itraconazole is contraindicated. If considered necessary, monitor for adverse effects and adjust dose.</li><li>Phospodiesterase-5 inhibitors (avanafil, sildenafil, vardenafil) — avoid concurrent use with avanafil; reduce dose of sildenafil or vardenafil.</li><li>Benzodiazepines (alprazolam, triazolam, midazolam) — dose reductions may be required.</li><li>Calcium-channel blockers (amlodipine, verapamil) — monitor for adverse effects.</li><li>Colchicine — dose adjustment may be necessary.</li><li>Corticosteroids (budesonide, dexamethasone) — avoid concurrent use.</li><li>Digoxin — monitor the effects of digoxin; digoxin dose may need to be reduced by 50–75%.</li><li>Disopyramide — avoid concurrent use.</li><li>Domperidone — possible increased risk of ventricular arrhythmias. Avoid concurrent use.</li><li>Eplerenone — concurrent use is contraindicated.</li><li>Ergot alkaloids (such as ergotamine and ergometrine) — increased risk of ergotism. Concurrent use is contraindicated.</li><li>Ivabradine — concurrent use is contraindicated.</li><li>Mizolastine — monitor for adverse effects.</li><li>Oral anticoagulants (warfarin, apixaban, dabigatran). — Monitor for adverse effects and adjust doses if required.</li><li>Pimozide — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Quinidine — increased risk of torsades de pointes. Concurrent use is contraindicated, but if considered necessary, monitor for adverse effects and reduce dose if required.</li><li>Ranolazine — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Reboxetine — monitor for adverse effects and adjust dose if required.</li><li>Solifenacin — restrict dose of solifenacin to 5 mg daily.</li><li>Statins (lovastatin, simvastatin) — avoid concurrent use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>]</p><!-- end field c2e40277-c142-475b-923b-a8d4013e9b76 --><!-- end item 72c03f2c-cccf-4d11-9efa-a8d4013e9abb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}